- Home
- AMS vs NRSN Comparison
AMS vs NRSN Comparison
Compare AMS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- NRSN
- Stock Information
- Founded
- AMS 1980
- NRSN 2017
- Country
- AMS United States
- NRSN Israel
- Employees
- AMS N/A
- NRSN N/A
- Industry
- AMS Medical Specialities
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- NRSN Health Care
- Exchange
- AMS Nasdaq
- NRSN Nasdaq
- Market Cap
- AMS 21.1M
- NRSN 17.8M
- IPO Year
- AMS N/A
- NRSN 2021
- Fundamental
- Price
- AMS $3.22
- NRSN $1.14
- Analyst Decision
- AMS
- NRSN Hold
- Analyst Count
- AMS 0
- NRSN 1
- Target Price
- AMS N/A
- NRSN N/A
- AVG Volume (30 Days)
- AMS 14.9K
- NRSN 360.5K
- Earning Date
- AMS 11-13-2024
- NRSN 12-31-2024
- Dividend Yield
- AMS N/A
- NRSN N/A
- EPS Growth
- AMS 779.12
- NRSN N/A
- EPS
- AMS 0.61
- NRSN N/A
- Revenue
- AMS $24,969,000.00
- NRSN N/A
- Revenue This Year
- AMS $29.39
- NRSN N/A
- Revenue Next Year
- AMS $16.22
- NRSN N/A
- P/E Ratio
- AMS $5.58
- NRSN N/A
- Revenue Growth
- AMS 20.83
- NRSN N/A
- 52 Week Low
- AMS $2.33
- NRSN $0.51
- 52 Week High
- AMS $4.60
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- AMS 47.26
- NRSN 56.63
- Support Level
- AMS $3.15
- NRSN $0.80
- Resistance Level
- AMS $3.59
- NRSN $1.29
- Average True Range (ATR)
- AMS 0.15
- NRSN 0.13
- MACD
- AMS 0.00
- NRSN 0.01
- Stochastic Oscillator
- AMS 17.78
- NRSN 68.75
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.